The Green Genes column focuses on biotechnology research and uses of biotechnology for crop improvement, medical and veterinary biologics, alternative fuels, and environmental remediation. Plant-based technologies and crop modification techniques show promise for benefits to global health and the environment. Simultaneously, biotechnology research and crop products must be safe for the environment (flora and wildlife), agriculture, and humans. This column provides biosafety professionals with background information, reviews of current research, and interdisciplinary insight to inform biological risk assessment and institutional biosafety programs for plant research. Green Genes topics are broadly applicable but primarily focus on US research settings and jurisdictions. Please email any comments, suggestions, or insights to Malendia Maccree at mmmaccree@ucanr.edu.
The New Wave of Gene-Editing Technologies in Plants
The recent application of novel gene-editing technologies to plants represents the most important development in crop biotechnology since the introduction of genetic engineering with Agrobacterium in the early 1980s. Gene-editing technologies based on sequence-specific nucleases (SSNs)-such as zinc finger nucleases, CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 systems, and transcription activator-like effector nucleases-offer greater precision in genome modification and are capable of advancing plantbreeding efforts in new ways. Although these promising technologies are being tested and utilized by research groups worldwide to modify plant genomes, there are still hurdles to overcome before the technologies can be used in commercial crop development. This column provides a brief overview of current developments, and readers are encouraged to explore the cited references for more details of the scientific and regulatory topics.
How Do These New Technologies Work in Plants, and How Are They Used?
A number of excellent reviews and commentaries have been published outlining the current use of these technologies in plants. [1] [2] [3] [4] [5] To date, the majority of high-impact research with SSNs has been reported in animal cellular systems as well as human cell lines. Schaeffer and Nakata 4 provide a helpful summary table of current work in CRISPR systems.
Although work in plants lags somewhat behind that of animal systems, SSNs have been tested and reported in model plant systems as well as in a few major crop plants. The SSN technology can be introduced to plant cells using traditional Agrobacterium-mediated transformation (AMT), by physical bombardment, or through viral technologies. The system can be used to alter the plant genome by exogenous introduction of the required SSN machinery and components, or the genes that encode the nuclease machinery can stably integrate into the plant genome to enable the endogenous production of the essential ingredients for gene editing. Once introduced to plant cells, the nucleases seek out a specific site in the host DNA where they produce a double-stranded break (DSB) in the DNA. The damaged DNA triggers the plant's innate DNA repair mechanisms, and the DSB is repaired by either nonhomologous end joining (NHEJ) or homologous recombination (HR). Different types of nucleases and varied experimental conditions drive the gene-editing event toward either NHEJ or HR.
The types of genetic modifications conferred to the plant typically fall into 3 groups: (1) targeted deletion of nucleotides to cause gain or loss of function; (2) use of the introduced nucleic acid template to guide the repair of the genomic DNA with no new genetic material being integrated into the genome; and (3) integration of new genetic material into the DSB site. The process of HR allows for the insertion of DNA fragments at the DSB site where the NHEJ process is more often used to produce smaller nucleotide changes to alter gene function without the addition of exogenous nucleic acids. Meganucleases and zinc finger nuclease technologies generate mutants for basic gene expression analyses. 5 CRISPR/Cas9 technology holds great promise for the cotransformation of multiple genetic elements in 1 transformation vector and for facilitating insertions or deletions of relatively large segments of DNA, enabling examinations of transgene inserts and alteration of multigene pathways in plants. 4 
What Do These Technologies Offer for Crop Research and Development?
Current uses of SSNs in plants tend to focus on basic science research and crop development. The precision of SSNs allows for targeting of specific genes within the plant genome, which presents a significant improvement over the random nature of other mutagenesis, AMT, or transposon-based systems. SSNs have the attractive feature of producing homozygous mutants in the F0 generation, saving the time and effort needed to produce and screen F1 progeny. These 2 features have the potential to accelerate gene discovery efforts in plant species. Crop development efforts have focused on the targeting of specific genes for gain or loss of function or on using SSNs to more efficiently stack genetic elements in genetically modified crops without the need for multiple sequential transformations and breeding crosses. 4 What Are the Drawbacks and Risks of the SSNs?
Much of the effort in the current development of SSN systems is aimed at producing reliable systems optimized for specific plant species. 4, 5 Although off-target insertions are a known drawback of SSNs 4,5 and even though errant inversions or duplications have been reported with some systems, 3 this is not a random event as with AMT. Specificity of insertion sites can facilitate screening of mutants for aberrant insertion events. In the effort to achieve a crop product that is as close as possible to its genetic progenitor, most crop developers aim to eliminate selectable marker genes and other elements not derived from plant DNA in the final crop product. One key drawback of many current genome modification technologies is the necessity for an expressed marker to aid the selection of transformed tissues. To address this issue, modified plants can be backcrossed with unaltered plants to segregate and eliminate markers from progeny populations based on Mendelian genetics. Still, some important crop plants do not have reproductive characteristics that make them amenable to this type of marker removal, and these types of backcrosses can be laborious and time-consuming. New gene-editing technologies show promise as tools to remove undesirable genes such as markers. These features, which enhance precision and the efficiency of plant genome modifications, play a key role in lowering the risk of undetected detrimental crop modifications being carried through to a commercial product. In considering the benefits of precision gene engineering in plants, recognizing that the site specificity of the nuclease is only as robust as the currently available genetic data on plant species and varieties is also important. Several authors point out that successful application of these new technologies requires a parallel commitment to high-quality bioinformatics tools and sequence data from plants. 4, 5 Continued work and investment are required to resolve procedural and technical drawbacks before SSNs will be used routinely to produce new crops for commercial use, but a growing body of research indicates that these technologies offer improved accuracy and safety over existing AMT-based technologies.
What Is the Status of Current Regulations?
Novel and emerging technologies are never without controversy, particularly in the world of biotechnology. Crops produced with SSN technologies are not known to present new or greater risks than crops produced through existing technologies; however, they may fall outside current regulatory classifications for products of recombinant DNA technologies in some jurisdictions. As this field of crop modification is newly emerging and not yet aligned with existing regulations, a number of authors have examined the issue of regulatory oversight from the perspectives of academia and crop development on both the US and international scale. [6] [7] [8] [9] While the research community may have reached consensus on the distinctions among the various products of gene-editing technologies based on the presence or absence of integrated genetic elements, these technologies highlight the limitations of the product-based coordinated framework for the review of genetically modified organisms in the United States 10 and process-based classifications in European Union countries. 11 Camacho et al 7 provide a particularly relevant and comprehensive analysis of the current regulatory landscape in the United States, pointing to several new technologies that ''fly beneath the regulatory radar'' and calling for a reasonable level of oversight in these new areas. It is conceivable within the current regulatory landscape for an institutional biosafety committee in the United States to face review of an outdoor release of a genetically modified organism that is not specifically regulated by any federal agency. As the National Institutes of Health guidelines do not offer guidance for confinement or outdoor use of genetically modified organisms 12 and because most institutional biosafety committees do not have access to reviewers with expertise or knowledge in field trials of crops, this scenario presents a troubling oversight conundrum and potential liability concern for public institutions and public researchers.
Meanwhile, developments in the research community and crop development sphere are mirrored in the recent actions of the US Department of Agriculture (USDA). In a Federal Register notice on March 4, 2015, the USDA Animal and Plant Health Inspection Service announced the withdrawal of its 2008 proposed rule for a tiered system of evaluation and approval that would have amended the regulations for certain genetically engineered organisms. 13 This action taken by the USDA leaves the United States to abide by 1990s-era regulations, but it also provides the agency new freedom to initiate much-needed discussions with stakeholders. The timing is right and the need great for biosafety professionals and the biosafety community as a whole to step in to take a seat at the table in this important discussion.
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